Examining Anti-Claudin-1 (CLDN1) Monoclonal Antibodies in Development for Liver, Kidney & Lung Fibrosis as a Novel Mechanism to Reverse Fibrosis
Time: 12:00 pm
day: Day Two
Details:
- Discover how lixudebart, a first-in-class monoclonal antibody, selectively binds to exposed Claudin-1 in fibrotic tissue, blocking fibrotic signaling and breaking down the collagen barrier to preserve or restore organ function in liver, kidney, and lung fibrosis
- Gain insights into the clinical development of lixudebart, including ongoing and planned Phase 2 trials for kidney and lung fibrosis, as well as a Phase 1b study in liver fibrosis, highlighting its safety, tolerability, and potential therapeutic benefits
